Dr. Reddy’s files 20-F annual report for 2026

Dr. Reddy’s Laboratories Limited has submitted a Form 6-K to notify investors that it filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026 with the U.S. Securities and Exchange Commission.

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited has submitted a Form 6-K to notify investors that it filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026 with the U.S. Securities and Exchange Commission. The report contains annual consolidated financial statements prepared under International Financial Reporting Standards as issued by the International Accounting Standards Board. The Form 20-F is also available on the company’s website for public access.

Key Figures

Fiscal year end: March 31, 2026 Form 20-F filing date: May 30, 2026

2 metrics

Fiscal year end March 31, 2026 Period covered by the Form 20-F annual report

Form 20-F filing date May 30, 2026 Date the annual report was filed with the U.S. SEC

Key Terms

Form 6-K, Form 20-F, International Financial Reporting Standards (IFRS), International Accounting Standards Board (IASB), +1 more

5 terms

Form 6-K regulatory

"SECURITIES AND EXCHANGE COMMISSION Form 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Form 20-F regulatory

"Annual Report in Form 20-F of the Company, containing annual consolidated financial statements"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

International Financial Reporting Standards (IFRS) financial

"financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board"

A set of globally accepted accounting rules companies use to prepare financial statements so their numbers speak the same language across borders. For investors, IFRS matters because it makes it easier to compare profitability, assets and liabilities between companies the way a common recipe or measuring tape lets you judge two cakes or two rooms fairly, which helps assess value and risk more reliably.

International Accounting Standards Board (IASB) financial

"IFRS, as issued by International Accounting Standards Board (IASB)"

An independent body that creates the rules companies use to prepare their financial statements (known as IFRS), so reports from different countries follow the same basic playbook. For investors this matters because consistent rules make company results easier to compare, reduce surprises and help you judge risk and value more reliably—like using the same measuring tape when comparing lengths across different projects.

Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regulatory

"Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dr. Reddy’s Laboratories (RDY) disclose in this Form 6-K?

Dr. Reddy’s disclosed that it filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026 with the U.S. SEC. The company also noted that this report is available on its website for investors and stakeholders to review.

What period does Dr. Reddy’s (RDY) 20-F annual report cover?

The Form 20-F annual report for Dr. Reddy’s covers the fiscal year ended March 31, 2026. This means all consolidated financial information and disclosures in that filing relate to the company’s operations and performance during that specific twelve-month period.

Under which accounting standards is Dr. Reddy’s (RDY) 20-F prepared?

Dr. Reddy’s prepares its Form 20-F annual report using consolidated financial statements under International Financial Reporting Standards (IFRS). These standards are issued by the International Accounting Standards Board, providing a globally recognized framework for the company’s financial reporting.

Where can investors access Dr. Reddy’s (RDY) Form 20-F for 2026?

Investors can access Dr. Reddy’s Form 20-F for the fiscal year ended March 31, 2026 on the company’s website. The intimation states that the full annual report is available via an online link for public reference and regulatory compliance needs.

Why did Dr. Reddy’s (RDY) issue this intimation under SEBI Regulation 30?

Dr. Reddy’s issued this intimation under SEBI Regulation 30 to formally notify Indian stock exchanges that its Form 20-F annual report has been filed. This ensures coordinated disclosure across Indian and U.S. markets and keeps domestic investors informed of the SEC filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 06:24 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

May, 2026

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                               Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                               No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated May 30, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: May 30, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

Exhibit 99.1

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel:       + 91 40 4900 2900 Fax:     + 91 40 4900 2999 Email:   mail@drreddys.com Web:    www.drreddys.com

May 30, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that Annual Report in Form 20-F of the Company, containing annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 30, 2026.

The Annual Report in Form 20-F is also available on the Company’s website at:

https://www.drreddys.com/cms/sites/default/files/2026-05/Form_20F_March_2026.pdf

This is for your information and records.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99-1 23.5 KB